TRVI
Trevi Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.95
−1.71%Next report
Analyst consensus
- Next report date
- Nov 12, 2026
- EPS estimate
- -$0.13
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.11
- EPS estimate
- -$0.11
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 9
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +7.2%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $29
- PT range
- $24 – $36
- Analysts
- 6
6 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.11 | -$0.11 | Miss -0.49% | — |
| May 5, 2026 | -$0.07 | -$0.09 | Miss -28.57% | — |
| Mar 17, 2026 | -$0.10 | -$0.06 | Beat 37.87% | — |
| Nov 13, 2025 | -$0.10 | -$0.08 | Beat 20.00% | — |
| Aug 7, 2025 | -$0.10 | -$0.09 | Beat 10.00% | — |
| May 8, 2025 | -$0.13 | -$0.09 | Beat 30.77% | — |
| Mar 18, 2025 | -$0.12 | -$0.11 | Beat 8.33% | — |
| Aug 8, 2024 | -$0.11 | -$0.12 | Miss -9.09% | — |
| Mar 20, 2024 | -$0.10 | -$0.08 | Beat 20.00% | $176.0K |
| Nov 9, 2023 | -$0.09 | -$0.08 | Beat 11.11% | — |
| Aug 10, 2023 | -$0.09 | -$0.07 | Beat 22.22% | — |
| May 11, 2023 | -$0.08 | -$0.06 | Beat 25.00% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 12, 2026